Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Aligos Therapeutics
About
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
- 101 - 250
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $125M
- Industries
- Biotechnology
- Founded date
- Apr 12, 2018
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 10, 2020 | Series B | $125M | 1 | — | — | Detail |
| Jan 1, 2018 | Series A | $100M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Versant Ventures
|
— | Series B |
